Article Figures & Data
Figures
- FIGURE 1.
Overall Kaplan–Meier survival curves of patients in group A (treated) and group B (nontreated) (P = 0.019).
- FIGURE 2.
(A) 131I-MIBG imaging of patient 18 during radionuclide therapy shows high uptake in multiple liver metastases and primary site. (B) Fifteen months later, 123I-MIBG imaging shows partial remission, with only faint uptake in primary site.
- FIGURE 3.
Progression-free Kaplan–Meier survival curves of patients in group A (treated) and group B (nontreated) (P = 0.024).
- FIGURE 4.
Event-free Kaplan–Meier survival curves of patients in group A (treated) and group B (nontreated) (P = 0.019).
Tables
Patient Group Age (y) Sex Primary tumor Primary site Secondary site Previous treatment Ongoing treatment Interval between diagnosis and RT (y) 1 A 63 F Carcinoid Midgut L, N, C Sur, Chem — 13 2 A 53 M NET Unknown L, N, C Sur, Chem — 3 3 A 57 M Carcinoid Pancreas L Sur, Chem Oct 400 mg 10 4 A 52 F Carcinoid Unknown N Sur, Chem Oct 400 mg 8 5 A 56 M Carcinoid Midgut L, N Chem Oct 600 mg 1.5 6 A 59 M Carcinoid Midgut L, N, C Sur, Chem Lan 30 mg 0.75 7 A 64 M NET Pancreas L Sur, Chem — 3 8 A 64 F NET Unknown L, N, C Chem — 8 9 A 71 M Vipoma Pancreas L, B Chem, Rad Oct 600 mg, analgesic 7 10 A 66 F Carcinoid Midgut L, B Chem Oct 400 mg 4 11 A 80 M Carcinoid Unknown L, N Sur, Chem Oct 1,000 mg, parenteral nutrition 15 12 A 57 M NET Pancreas L, B Chem — 1.5 13 A 68 F Carcinoid Midgut L, N, C Sur, Chem Oct 1,500 mg 26 14 A 62 F Carcinoid Midgut L Sur, Chem Lan 30 mg 15.75 15 A 49 M NET Hindgut L, B, C Sur, Chem — 8.25 16 A 68 M Gastrinoma Unknown L Sur, Chem Oct 300 mg 3 17 A 61 F Carcinoid Midgut L, N, B Chem Oct 400 mg 5 18 A 53 M Carcinoid Midgut L, N Chem — 1.8 19 A 70 F NET Midgut L Chem Oct 1,500 mg 15 20* A 37 M Vipoma Pancreas L, P Chem Analgesic 6 Mean ± SD 61.8 ± 7.8 12 M/ 8 F — — — 7.9 ± 6.6 21 B 62 M Gastrinoma Pancreas L, B Chem — 0.5 22 B 74 F Carcinoid Midgut L, C Chem — 0.7 23 B 40 F Gastrinoma Pancreas L Chem Oct 400 mg 0.7 24 B 58 M Gastrinoma Pancreas L Sur, Chem — 16.6 25 B 79 M NET Pancreas L, N, A Sur, Chem — 1.7 26 B 50 F Gastrinoma Pancreas L, N, C Chem, ChEmb Oct 200 mg 18 27 B 71 M Glucagonoma Pancreas L, N Sur, Chem Oct 400 mg 5 28 B 59 M Gastrinoma Pancreas N, C, A Sur, Chem Oct 600 mg 18 29 B 67 F Carcinoid Midgut L Sur, Chem Oct 750 mg 15 30 B 65 F Gastrinoma Pancreas L Sur, Chem — 18 31 B 81 F Carcinoid Midgut N, B, C — Lan 30 mg 5 32 B 85 F Insulinoma Pancreas L, N Chem Oct 400 mg 21.75 Mean ± SD — 65.9 ± 13.2 5 M/ 7 F — — — — — 10.0 ± 8.4 P between groups NS NS NS RT = radionuclide therapy; NET = neuroendocrine tumor; L = liver; N = lymph nodes; C = chest; Sur = surgery; Chem = chemotherapy; Oct = Octreotide; Lan = Lanreotide; B = bone; Rad = radiotherapy; P = peritoneum; A = adrenal; ChEmb = chemoembolization; NS = nonsignificant.
↵* Patient excluded from quantitative analysis during follow-up.
Patient Group Age (y) Sex Primary tumor Pretherapeutic imaging Radionuclide therapy Follow-up (mo) 111In-Pentetreotide uptake (grade) 131I-MIBG uptake (grade) Tracer Administered activity (GBq) Number of treatment† 1 A 63 F Carcinoid 3 0 111In-Pentetreotide 20.0 1 17 2 A 53 M NET 3 1 111In-Pentetreotide 22.1 1 23 3 A 57 M Carcinoid 4 0 111In-Pentetreotide 17.2 1 20 4 A 52 F Carcinoid 4 0 111In-Pentetreotide 19.7 2 57 5 A 56 M Carcinoid 3 2 111In-Pentetreotide 20.6 2 55 6 A 59 M Carcinoid 3 1 111In-Pentetreotide 21.4 2 55 7 A 64 M NET 3 0 111In-Pentetreotide 20.2 1 42 8 A 64 F NET 3 0 111In-Pentetreotide 20.3 1 36 9 A 71 M Vipoma 3 0 111In-Pentetreotide 21.5 1 11 10 A 66 F Carcinoid 3 0 111In-Pentetreotide 20.8 1 5 11 A 80 M Carcinoid 3 1 111In-Pentetreotide 20.4 1 24 12 A 57 M NET 4 2 111In-Pentetreotide 21.4 1 7 13 A 68 F Carcinoid 3 3 131I-MIBG 5.8 0.66 22 14 A 62 F Carcinoid 3 3 131I-MIBG 18.7 1 28 15 A 49 M NET 3 3 131I-MIBG 12.9 1 15 16 A 68 M Gastrinoma 3 2 111In-Pentetreotide 22.5 1 22 17 A 61 F Carcinoid 3 1 111In-Pentetreotide 21.6 1 12 18 A 53 M Carcinoid 3 3 131I-MIBG 20.5 1 41 19 A 70 F NET 3 3 131I-MIBG 14.3 1 12 20* A 37 M Vipoma 4 2 111In-Pentetreotide 13.1 0.66 0 Mean ± SD — — — — 18.8 ± 4.2 — 26.5 ± 16.5 21 B 62 M Gastrinoma 3 0 — 0 0 2 22 B 74 F Carcinoid 3 2 — 0 0 1.5 23 B 40 F Gastrinoma 4 1 — 0 0 10 24 B 58 M Gastrinoma 3 1 — 0 0 12 25 B 79 M NET 0 0 — 0 0 8 26 B 50 F Gastrinoma 3 0 — 0 0 0.25 27 B 71 M Glucagonoma 3 0 — 0 0 14 28 B 59 M Gastrinoma 3 0 — 0 0 8 29 B 67 F Carcinoid 3 0 — 0 0 15 30 B 65 F Gastrinoma 3 0 — 0 0 15 31 B 81 F Carcinoid 3 3 — 0 0 3 32 B 85 F Insulinoma 3 0 — 0 0 12 Mean ± SD — — — — — 9.9 ± 4.6 P between groups P = 0.001 Patient Group Age (y) Sex Primary tumor Death (mo) Radiologic response at 3 mo Duration of radiologic response (mo) Biologic response Clinical status Global response 1 A 63 F Carcinoid 17 Progression — — None Not beneficial 2 A 53 M NET — Stabilization 16 NSE, −37% Improvement Beneficial 3 A 57 M Carcinoid 20 Stabilization 20 — Improvement Beneficial 4 A 52 F Carcinoid — Stabilization 26 — Improvement Beneficial 5 A 56 M Carcinoid — Stabilization 12 — Improvement Beneficial 6 A 59 M Carcinoid — Stabilization 11 — Improvement Beneficial 7 A 64 M NET — Stabilization 34 — None Beneficial 8 A 64 F NET — Stabilization 24 — None Beneficial 9 A 71 M Vipoma 11 Stabilization 11 — Improvement Beneficial 10 A 66 F Carcinoid 5 Stabilization 5 — Aggravation Not beneficial 11 A 80 M Carcinoid — Stabilization 19 5-HIAA, −48% None Beneficial 12 A 57 M NET — Stabilization 4 5-HIAA, −58% Improvement, then aggravation Not beneficial 13 A 68 F Carcinoid — Stabilization 12 — Improvement Not beneficial 14 A 62 F Carcinoid — Stabilization 12 — None Beneficial 15 A 49 M NET — Stabilization 8 — None Beneficial 16 A 68 M Gastrinoma 22 Progression — — Aggravation Not beneficial 17 A 61 F Carcinoid — Stabilization 12 — None Beneficial 18 A 53 M Carcinoid — Partial regression 18 5-HIAA, normalized Improvement Beneficial 19 A 70 F NET — Stabilization 10 — Improvement Beneficial 20* A 37 M Vipoma 1.5 — — — — — 21 B 62 M Gastrinoma 2 — — — — — 22 B 74 F Carcinoid 1.5 — — — — — 23 B 40 F Gastrinoma — Progression — — — — 24 B 58 M Gastrinoma — Stabilization 12 — — — 25 B 79 M NET — Stabilization 8 — — — 26 B 50 F Gastrinoma 0.25 — — — — — 27 B 71 M Glucagonoma — Stabilization 6 — — — 28 B 59 M Gastrinoma — Progression — — — — 29 B 67 F Carcinoid — Stabilization 15 — — — 30 B 65 F Gastrinoma — Progression — — — — 31 B 81 F Carcinoid 3 — — — — — 32 B 85 F Insulinoma 13 Stabilization 12 — — — NET = neuroendocrine tumor; NSE = neuron-specific enolase; 5-HIAA = 5-hydroxyindoleacetic acid.
↵* Patient excluded for quantitative analysis during follow-up.
In this issue
Jump to section
Related Articles
Cited By...
- Anti-SSTR2 Antibody-Drug Conjugate for Neuroendocrine Cancer Therapy
- A population-based study of outcomes in patients with gastrointestinal neuroendocrine tumours
- Targeted Radionuclide Therapy: Proceedings of a Joint Workshop Hosted by the National Cancer Institute and the Society of Nuclear Medicine and Molecular Imaging